// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Comparison of the lung ventilation assessed by a full-scale airway network flow model and xenon-enhanced dual-energy CT of patients with COPD

Minsuok Kim - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Effect of age, gender and body habitus upon exhaled breath volatiles in COPD and health

Liesl Carr - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Factors associated with physician assessment of severity of asthma or COPD in NOVELTY

Alberto Papi - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Asthma

N/A

Comparison of individual items of COPD Assessment Test (CAT at baseline in the EMAX and IMPACT trials

Paul Jones - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Systematic assessment detects respiratory problems in illness-susceptible athletes

James H. Hull - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Nitric oxide

Predicting frequent exacerbations in a severe asthma centre

Clara Green - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Practicality and clinical utility of cardiopulmonary exercise testing to investigate complex breathlessness in severe asthma

Amanda Vigus - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Association between cough frequency and T2 inflammation in severe asthma

Joshua Holmes - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Nitric oxide

The Cretan Registry of the use of Biologics in Severe Asthma (CREBS of the University Hospital of Heraklion,Greece

Katerina Antoniou - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Cretan Severe Asthma Registry

Katerina Antoniou - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

The relationship between lung function and BAL return in severe asthma

David Hill - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Is the minimally clinically important difference (MCID fit for purpose? A planned study using the SAQ

Joseph Lanario - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Targeted literature review: burden of disease associated with severe and uncontrolled asthma in France, Germany, Italy, Spain and the UK

Arnaud Bourdin - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Predictors of sputum eosinophilia in severe asthma

Adnan Azim - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Quality of life in severe asthma measured by SAQ and EQ5D questionnaires as a function of clinically relevant cut off points

Joseph Lanario - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2015 and GOLD 2019 staging systems: a pooled analysis of individual patient data

Elena Garcia Castillo - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Comparison of Cough Assessment by Visual and Airflow Changes in the Guinea Pig Model of Citric Acid-Induced Cough

Laurence Tilley - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

histamine

Is the strength of the type-2 (T2 inflammatory biomarker signal important in determining the burden of disease in severe asthma (SA?

Lauren Fox - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Chronic cough in patients presenting to a tertiary cough clinic

Claire Slinger - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Sex differences in COPD outcome in 5,355 women with COPD: A new analysis of the 3CIA study

Tamara Alonso Perez - European Respiratory Society (ERS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Dyspnea

N/A

Copyright © 2026. QuantiNova All rights reserved